SCHEMBL2164369

SCHEMBL2164369

Oc1cc(-c2ccc(CCF)cc2)cc2nc3ccccc3n12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.37
ALDH1A1 P00352 4/20 0.37
GAA P10253 3/20 0.37
HPGD P15428 3/20 0.37
MAPK1 P28482 1/20 0.37
POLB P06746 3/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
MAPT P10636 2/20 0.35
MCL1 Q07820 1/20 0.35
PPARG P37231 2/20 0.34
ADORA1 P30542 3/20 0.33
ADORA2A P29274 2/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163340 0.83 ADORA2A (0.45) KDM4EALDH1A1GAAHPGDMAPK1
SCHEMBL12323537 0.82 PRF1 (0.44) KDM4EALDH1A1POLBNPC1RAB9A
SCHEMBL2164541 0.77 ALK (0.39) KDM4EALDH1A1GAAHPGDPOLB
SCHEMBL2182908 0.69 KDM4E (0.42) KDM4EALDH1A1GAAHPGDMAPK1
SCHEMBL2164371 0.68 MIF (0.37) KDM4EALDH1A1GAAHPGDMAPK1
SCHEMBL17151120 0.64 TAAR1 (0.58) ALDH1A1GAASMN1; SMN2LMNA
SCHEMBL9553164 0.63 MAOB (0.52)
SCHEMBL9552986 0.63 MAOB (0.52)
SCHEMBL9362915 0.63 CSNK1A1 (0.44) KDM4EALDH1A1GAAHPGDMAPK1
SCHEMBL2163032 0.62 ALDH1A1 (0.60) KDM4EALDH1A1GAAHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 KDM4E 4835/4885ALDH1A1 3926/4885GAA 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.